{"organizations": [], "uuid": "0907b3e22dc4ddddf67fc2d076c63aa2fe76fd5f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180508.html", "section_title": "Archive News &amp; Video for Tuesday, 08 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-oncosec-expands-relationship-with/brief-oncosec-expands-relationship-with-merck-for-combination-of-immunopulse-il-12-and-keytruda-idUSB8N1LI03M", "country": "US", "domain_rank": 408, "title": "BRIEF-Oncosec Expands Relationship With Merck For Combination Of Immunopulse Il-12 And Keytruda", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.982, "site_type": "news", "published": "2018-05-08T19:35:00.000+03:00", "replies_count": 0, "uuid": "0907b3e22dc4ddddf67fc2d076c63aa2fe76fd5f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-oncosec-expands-relationship-with/brief-oncosec-expands-relationship-with-merck-for-combination-of-immunopulse-il-12-and-keytruda-idUSB8N1LI03M", "ord_in_thread": 0, "title": "BRIEF-Oncosec Expands Relationship With Merck For Combination Of Immunopulse Il-12 And Keytruda", "locations": [], "entities": {"persons": [{"name": "merck", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "oncosec medical inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 8 (Reuters) - OncoSec Medical Inc:\n* ONCOSEC EXPANDS RELATIONSHIP WITH MERCK, ANNOUNCES CLINICAL COLLABORATION TO EVALUATE COMBINATION OF IMMUNOPULSE IL-12 AND KEYTRUDA FOR TRIPLE NEGATIVE BREAST CANCER\n* ONCOSEC MEDICAL - PLANNED TRIAL WILL EVALUATE SAFETY, EFFICACY OF COMBINATION IN CERTAIN PATIENTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC TNBC\n* ONCOSEC MEDICAL SAYS UNDER COLLABORATION AGREEMENT, ONCOSEC WILL SPONSOR, FUND STUDY AND MERCK WILL PROVIDE KEYTRUDA\n* ONCOSEC MEDICAL SAYS ADDITIONAL DETAILS OF THE COLLABORATION WERE NOT DISCLOSED Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-08T19:35:00.000+03:00", "crawled": "2018-05-09T12:30:56.001+03:00", "highlightTitle": ""}